NEW YORK (GenomeWeb News) – Warnex announced today a binding agreement to sell its Bioanalytical Services division to contract research organization Biotrial Research for C$6 million (US$6 million).

As a result of the sale, Warnex will no longer have any material active business operations but will maintain its corporate headquarters, the Laval, Quebec-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.